What happened Shares of Inovio Pharmaceuticals (INO 2.17%) were crashing 27.4% as of 10:17 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.
Full Answer
Why are Inovio Pharmaceuticals shares down 8% Thursday?
Jun 10, 2021 · Shares of Inovio Pharmaceuticals ( INO 5.85% ) were sinking 8.8% as of 11:13 a.m. EDT on Thursday. The company didn't announce any new developments, and today's sell-off appears to be due to ...
Is Inovio (Ino) stock set to rebound?
Apr 23, 2021 · What happened Shares of Inovio Pharmaceuticals ( INO 2.17%) were crashing 27.4% as of 10:17 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense...
Will Inovio’s VGX-3100 be another winning year for stocks?
What happened After regulators notified DNA vaccine maker Inovio Pharmaceuticals ( INO -3.53%) that they are placing its lead compound on clinical hold, …
Which stocks are down 50% from their 52-week highs?
Shares of Inovio Pharmaceuticals ( INO 5.06%) declined on Friday after investment bank Stifel cut its rating on the biotech stock. So what Stifel analyst Stephen Willey reduced his rating on...
The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) were crashing 27.4% as of 10:17 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.
So what
The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.
Now what
The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.
Shares plunge after the FDA places the company's lead compound on clinical hold
Brian Feroldi has been covering the healthcare and technology industries for The Motley Fool since 2015. Brian's investing strategy is to buy high-quality companies and then let compounding work its magic. See all of his articles here. Follow @brianferoldi
What happened
After regulators notified DNA vaccine maker Inovio Pharmaceuticals ( NASDAQ:INO) that they are placing its lead compound on clinical hold, shares fell by 13% as of 11:15 a.m. EDT on Monday.
So what
FDA officials told Inovio that they have ordered a clinical hold on the company's proposed phase 3 clinical trial for VGX-3100. This study has not yet been initiated, but Inovio had previously announced its intentions to start the trial before the end of the year.
Now what
VGX-3100 is the company's most advanced compound, so it is no surprise that the markets are reacting negatively to the news.
One analyst thinks the biotech's shares have come too far too fast
Joe honed his investing skills as an analyst for Stock Advisor, Supernova, and Fool One. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns during its existence.
What happened
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) declined on Friday after investment bank Stifel cut its rating on the biotech stock.
So what
Stifel analyst Stephen Willey reduced his rating on Inovio's shares from buy to hold. Willey believes that after the stock's incredible gains in 2020 -- the stock is up a staggering 797% so far this year -- the risk-to-reward equation for investors is now "less palatable."
Now what
Not all analysts are bearish on Inovio's stock, however. On the same day that Willey cut his rating to hold, Cantor Fitzgerald analyst Charles Duncan reiterated his "overweight" rating on Inovio's shares and boosted his target price from $17 to $45.
Lingering disappointment over results announced on Tuesday and an FDA update are weighing on the stock
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) were crashing 14.6% lower as of 10:55 a.m. EDT on Wednesday after falling as much as 20.7% earlier in the day. The drop stemmed from two factors.
So what
Inovio's valuation is based entirely on investors' expectations for the company's pipeline. Any hint of bad news is going to cause the biotech stock to sink. And both factors behind Inovio's decline today are hints of bad news to some.
Now what
The primary thing for investors to watch now with Inovio is the biotech's pipeline progress. Inovio hopes to advance INO-4800 to a phase 2/3 clinical study after reviewing its phase 1 results with the FDA. The U.S. government's Operation Warp Speed is also funding a preclinical trial that includes INO-4800.
Why Inovio Stock Is Jumping Today
What happened Shares of Inovio Pharmaceuticals (NASDAQ: INO) were jumping 5.9% higher as of 11:07 a.m. EDT on Thursday after rising as much as 13.6% earlier in the session. The big gain came following Inovio's announcement that Brazilian regulators authorized the initiation of a phase 3 clinical study of COVID-19 vaccine candidate INO-4800.
Inovio Pharmaceuticals Stock Nears End Of Technical Pattern
Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Thursday after the company announced it received regulatory authorization from Brazil’s ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial for INO-4800. Inovio Pharmaceuticals stock was up 9.3% at $9.22 at last check.
Inovio To Start Global Late-Stage COVID-19 Vaccine Trial
The regulatory authority of Brazil has signed off Inovio Pharmaceuticals Inc's (NASDAQ: INO) global Phase 3 segment of its INNOVATE Phase 2/3 trial for INO-4800, DNA COVID-19 vaccine candidate. Related Content: Inovio's DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study.
Why Inovio's Stock Is Trading Higher Today
Inovio Pharmaceuticals Inc (NASDAQ: INO) is trading higher Thursday after the company announced it received regulatory authorization from Brazil's ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial for INO-4800, its DNA vaccine candidate for COVID-19.
UPDATE 2-Inovio to start COVID-19 vaccine trial after Brazil regulator's nod
Inovio Pharmaceuticals Inc said on Thursday it would start a large study for its experimental COVID-19 vaccine in the next few weeks, after the drugmaker received authorization from Brazil's regulatory agency.
2 Popular Robinhood Stocks I Wouldn't Buy With Free Money
Robinhood Markets is the company behind investing platform Robinhood. Particularly popular among younger generations, Robinhood has received a lot of praise because of its efforts to "democratize finance." Considering the stock market remains one of the best wealth generators for the common person, that is not a bad thing.
Is Inovio Stock A Buy Or A Sell As Second-Quarter Metrics Come Up Short?
Is INO stock a buy or a sell after second-quarter revenue missed and losses were wider than Inovio stock analysts expected?